HSBC's base case target suggests 10 per cent upside over the prevailing stock price. Its bull case target suggests 40 per ...

Brokerages have turned bullish over Biocon's growth prospects after the US FDA clearance of the drugmaker's Malaysia unit ...

The Indian market is expected to trade higher on January 15, supported by positive global cues. Nifty futures gained 0.51% on ...

According to reports, HSBC said that Biocon is well-placed for an operational turnaround, driven by key biosimilar launches ...

HSBC expects an operational turnaround for Biocon, driven by major biosimilar launches and a rebound in generics sales. The ...

Biocon has experienced a significant earnings decline over the past two years, led by a lack of potential approvals for the U ...

Clearance of Biocon's Malaysia unit puts an end to the drugmaker's regulatory hurdles and opens the door for the approval and ...

The Nifty50 had a gap-up opening at 23,216.50 on Tuesday and ended the day at 23,176.05, up 0.39% from Monday's close.

Shares of Biocon were in high demand on Monday after the pharmaceutical company's subsidiary Biocon Biologics' Johor Bahru ...

Shares of Biocon surged as much as 5 per cent during the trading session on Monday after the USFDA cleared Malaysia unit to ...

Biocon Ltd has broken out of the Symmetrical Triangle formation on daily charts, suggesting a potential rise in stock price.

Motilal Oswal (MOSL) has reiterated its "Buy" rating on HCL Technologies, setting a target price of Rs 2,400, which implies a ...